{
   "4": "the secondary trial records several pn adverse events, whereas the primary trial doesn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t.",
   "9": "the primary trial subjects recieving Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines. are administered it topically [twice/three times] daily for approximately [duration].",
   "58": "participants of cohort 1 in the primary trial and all participants of the secondary trial take [NUM] milligram of   DOSI PO QD.",
   "62": "The primary trial and the secondary trial are not studying PBR or PFS.",
   "76": "The primary trial studies PBR",
   "105": "The primary trial and the secondary trial are not studying PFS, PBR or DLTs.",
   "112": "The primary trial studies PBR",
   "123": "The primary trial and the secondary trial are not studying PBR or PFS.",
   "135": "Both the primary trial and the secondary trial had no cases of PNE"
}